Clinical trials: Lung Cancer, open to volunteers
Non Small Cell Lung Cancer, Lung Cancer
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC).
- Trial name
- NCT05401110
- Testing
- Osimertinib, Carotuximab
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Karen Reckamp, MD, MS
Non-Small-Cell Lung
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
- Trial name
- MAP (NCT07316062)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of functional compromised tissue to deliver sufficient dose to the…
- Trial name
- GuidedRT (NCT07355231)
- Testing
- Hyperpolarized xenon MRI
- Volunteers
- 10 people
- Sponsor
- Xemed LLC
Small Cell Lung Cancer ( SCLC ), Brain Injury
Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury
The study aims to enroll the small cell lung cancer(SCLC) who meet the indications for prophylactic cranial irradiation (PCI): patients with limited-stage SCLC who have achieved complete or partial remission after first-line…
- Trial name
- NCT07905937
- Testing
- PD-1 Inhibitor + Chemotherapy+PCI, chemotherapy+PCI
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Guizhou Medical University
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma.
- Conditions
- Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
- Trial name
- NCT05188859
- Testing
- Sintilimab+Anlotinib+Pemetrexed+Cisplatin
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Non-Small Cell Lung Cancer
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.
- Trial name
- NCT07415005
- Testing
- Lorlatinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Liver Cancer
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors.
- Conditions
- Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer
- Trial name
- NCT00451022
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Lung Cancer Screening, Lung Neoplasms
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screening do not receive it.
- Conditions
- Lung Cancer Screening, Lung Neoplasms, Smoking ( Cigarette), Early Detection of Cancer
- Trial name
- Empower LCS+ (NCT07711691)
- Testing
- Empower LCS, Call+ Telephone Navigation, Usual Care
- Where
- 57 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of California, Irvine
Lung Cancer Screening
C-Raven LDCT: Lung Cancer Screening Intervention
This study is a three-arm, randomized controlled pilot of a lung cancer screening intervention. The investigators will recruit participants ages 50-80 who are likely to meet lung cancer screening guidelines.
- Trial name
- C-Raven LDCT (NCT07819318)
- Testing
- Video/Brochure, Video/Brochure/Follow-up Call
- Volunteers
- 300 people
- Sponsor
- Johns Hopkins University
Robotics, Lung Cancer
SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC
Single-POrt Robotic-assisted thoracic surgery versus single-port video-assisted Thoracic Surgery major pulmonary resection for patients with non-small cell lung cancer (SPORTS trial): a single-center, a single blinded, randomized…
- Trial name
- SPORTS (NCT06202690)
- Testing
- Single-port robotic-assisted thoracic surgery, Single-port video-assisted thoracoscopic surgery
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
Precision medicine represents a major goal in oncology. It has its underpinning in the identification of biomarkers with diagnostic, prognostic, or predictive values.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Neuroendocrine Tumors
- Trial name
- ELEGANCE (NCT06735560)
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Nantes University Hospital
NSCLC, TNBC
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
This is a single-arm, multicenter, open-label Phase II clinical study evaluating the efficacy and safety of IMM2510 in combination with chemotherapy as first-line treatment in patients with stage IV metastatic or recurrent NSCLC…
- Trial name
- NCT06746870
- Testing
- IMM2510, Chemotherapy (pemetrexed + cisplatin/carboplatin), Chemotherapy (paclitaxel + cisplatin/carboplatin)
- Volunteers
- 148 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Small Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory.
- Trial name
- NCT06780137
- Testing
- Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab
- Where
- 48 sites in United States, Argentina and 10 more
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients.
- Trial name
- Relapsed SCLC (NCT06681220)
- Testing
- Stenoparib/Temozolomide, Lurbinectedin
- Where
- 11 sites in United States
- Volunteers
- 166 people
- Sponsor
- VA Office of Research and Development
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell…
- Trial name
- KYLIN-3 (NCT06970782)
- Testing
- Vebreltinib, PLB1004, Pemetrexed plus Carboplatin or Cisplatin
- Volunteers
- 278 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Lung Cancer
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase…
- Trial name
- NCT07241767
- Testing
- FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin, FH-006 ; SHR-1316 ; BP102, FH-006; SHR-1316 ; SHR-8068
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Lung Cancer
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
- Trial name
- NCT04814407
- Testing
- Blood-derived DNA methylation detection
- Where
- Taiwan
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic…
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
- Trial name
- NCT07824856
- Testing
- CT-guided percutaneous local ablation, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.